Why chronic diseases...

Medlab focus
Date:  2020-07-01
Author:   Medlab
Why chronic diseases

Medlab Clinical is a medical research and development facility researching and formulating novel therapeutics (e.g., nutraceuticals and pharmaceuticals) to improve health outcomes in early to moderate stage chronic illnesses.

Specifically, Medlab is heavily invested in Oncology co-morbidities, such as pain.

There are several core programs that encompass either novel discovery, delivery platform and/or repurposing generic drug.

Why chronic diseases...?

"The global epidemic of chronic illnesses are the next healthcare pandemic, unlike other diseases, chronic illnesses require a multifactorial and multi-disciplined approach in the hope of addressing the ever-increasing economy and humane burden. Therefore, biomedical research that is focused on improving the health and function of the community is of paramount importance. Medlab Clinical is dedicated to developing new therapeutics that improve chronic disease health outcomes, whether these be in prevention, maintenance, or curative." SEAN HALL CEO/MD

What are Chronic Diseases

Understanding the impact of chronic diseases is vital; the Australian Institute of Health Welfare (AIHW) claims chronic diseases (in Australia) accounted for 90% of all deaths in 2011

ADVANCED CANCER PAIN

Australia – 130,000 new patients every year. 
Source: What is Cancer: Facts and Figures. Cancer Council Australia, 2019.

PRE-DIABETES

USA – 86,000,000 and growing 
Source: Diabetes Risk, American Diabetes Association.

TYPE II DIABETES

USA – 30,000,000 and growing 
Source: Diabetes Risk, American Diabetes Association.

CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV)

70% - 80% of patients undergoing chemotherapy. 
Source: Transparency Market Research. CINV Existing and Pipeline Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014-2020. Accessed October 4, 2016

CARDIOVASCULAR DISEASE (CVD)

Australia – 1,200,000
Source: Australian Government, The Department of Health

USA – 85,600,000
Source: American Heart Association.

SEIZURES

Worldwide – 65,000,000
Source: Facts and Statistics: Epilepsy Action Australia.

MUCOSITIS

Over 40% of patients
Source: Radiation therapy and chemotherapy-induced oral mucositis (2007) Brazilian Journal of Otorhinolaryngology, Volume 73, Issue 4, July–August 2007, Pages 562-568.

CANCER: PROSTATE, BREAST AND BONE METASTASIS

Population numbers for both breast and prostate cancers with bone metastasis are growing, survival rates are improving, so patients live with pain longer.

The global cancer burden for all types of cancer is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018.

  • Worldwide, the total number of people who are alive within 5 years of a cancer diagnosis, called the 5-year prevalence, is estimated to be 43.8 million.
  • The increasing cancer burden is due to several factors, including population growth and ageing as well as the changing prevalence of certain causes of cancer linked to social and economic development.
  • Europe accounts for 23.4% of the global cancer cases and 20.3% of the cancer deaths, although it has only 9.0% of the global population.
  • The Americas have 13.3% of the global population and accounts for 21.0% of incidence and 14.4% of mortality worldwide.
  • Global patterns show that for men and women combined, nearly half of the new cases and more than half of the cancer deaths worldwide in 2018 are estimated to occur in Asia, in part because the region has nearly 60% of the global population.
  • Breast cancer is the most commonly diagnosed cancer in women globally and accounts for about one in 4 of all new cancer diagnoses. It is the fifth leading cause of death because the prognosis is more favourable at least in more developed countries.
  • Prostate cancer is the second most frequently diagnosed cancer in men globally and accounts for 13.5% of cancer deaths in men.

Source: press release 263, September 2018 Int Agency for Research on Cancer. 

US Prevalence of Bone Metastases 
In 2012, Hernandez R et al estimated that there were 330,000 adult patients living in the US with bone metastases secondary to all types of solid tumours.
Source: (Hernandez R et al, 2015)

In 2018, Damodaran et al analysed recent clinical trials in metastatic prostate cancer and estimated the median survival was 48 months.
Source: Urol Clin North Am, 2017; 44(4): 611–621

DEPRESSION

Australia - Outlays by governments and health insurers to provide mental health services in 2006-07 totalled $4.7 billion, representing 7.3% of all government health spending.
2017, The total cost to society was broken down into $974 million in health care costs and $11.8 billion in total productivity loss. Additional costs to governments included $1.23 billion in foregone income taxes and $12.9 billion in welfare benefits
Source: Fourth National Mental Health Plan: An Agenda For Collaborative Government Action In Mental Health 2009-2014, The magnitude of the problem. Australian Government Department of Health.

USA - The total economic burden of MDD is now estimated to be $210.5 billion per year.
Source: Center for Workplace Mental Health, Depression, Quantifying the Cost of Depression, American Psychiatric Association.

For every dollar spent on MDD direct costs in 2010, an additional $1.90 was spent on MDD-related indirect costs.
Source: Center for Workplace Mental Health, Depression, Quantifying the Cost of Depression, American Psychiatric Association.

Europe - The cost of mood disorders and anxiety in the EU is about €170 billion per year.
Source: Depression in Europe: facts and figures. World Health Organization, 2012.

Canada - The study commissioned by the MHCC makes it clear that the economic cost to Canada is at least $50 billion per year. This represents 2.8% of Canada’s 2011 gross domestic product. 
Source: Center for Workplace Mental Health, Depression, Quantifying the Cost of Depression, American Psychiatric Association.

COMMENTS 0

Tell us what you think login to share your thoughts.

ABOUT THE AUTHOR

Medlab Author
Medlab Author
Medlab

Medlab in-house Editor.